drugset / Trial / NCT02968680
Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma
Phase 1
Terminated
5 enrolled
University of Southern California
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This pilot phase I trial studies how well sonazoid-enhanced ultrasound works in detecting sentinel lymph node in patients with cutaneous melanoma. Sonazoid is a contrast agent that may make it easier to see if the tumor cells have spread to the sentinel lymph node using an ultrasound.
Timeline
- Start
- 2017-04-26
- Primary completion
- 2019-06-28
- Completion
- 2020-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Perflubutane | Diagnostic / imaging agent | — | Other |